Anifrolumab in systemic lupus erythematosus: a profile of its use

 

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest  Y. N. Lamb is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content. 

Ethics approval, Consent to participate and consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found _here

Abstract

Anifrolumab (Saphnelo™), an intravenously administered immunoglobulin G1 kappa monoclonal antibody targeting the type 1 interferon alpha receptor, is effective and generally well tolerated as an add-on to standard therapy in adults with moderate to severe systemic lupus erythematosus (SLE). Anifrolumab reduces overall disease activity in patients with moderate to severe SLE despite receiving stable standard-of-care treatment, based on the totality of evidence from randomized, double-blind, placebo-controlled, phase 2b and 3 clinical trials. Anifrolumab also has corticosteroid-sparing effects and reduces skin disease severity. Therapeutic benefits of anifrolumab appear to be sustained over longerterm

treatment. With respect to tolerability, anifrolumab recipients are at increased risk of infections (including herpes zoster). Additional long-term data are being collected in an ongoing extension of the phase 3 trials.

© Springer Nature Switzerland AG 2022